Insulet raises 2025 revenue guidance after Q3 sales rise 29.9% to $706.3 million
Insulet reported third-quarter 2025 revenue of $706.3 million, up 29.9%, and net income of $87.6 million, or $1.24 per diluted share, compared with $1.08 a year earlier. The company raised its full-year 2025 total revenue growth guidance to 28% to 29% in constant currency, from 24% to 27%, which supports the strong quarter for shareholders, though adjusted EBITDA margin fell 50 basis points.
Key points
- Q3 2025 revenue of $706.3 million rose 29.9%, or 28.2% in constant currency, above the high end of the 22% to 25% constant currency guidance range
- Q3 net income of $87.6 million, or $1.24 per diluted share, versus $77.5 million, or $1.08 per diluted share, a year earlier
- Full-year 2025 total revenue growth guidance raised to 28% to 29% in constant currency from 24% to 27%
- Adjusted operating margin guidance for 2025 narrowed to 17.3% to 17.5% from 17.0% to 17.5%
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.